Ptc Therapeutics (PTCT) Net Income towards Common Stockholders (2012 - 2026)

Ptc Therapeutics' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at -$2.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 100.32% year-over-year to -$2.8 million; the TTM figure through Mar 2026 stood at -$1.4 billion (down 339.61% YoY), while the FY2025 annual figure was -$555.9 million, down 53.02% from the prior year.
• Net Income towards Common Stockholders was -$2.8 million for Q1 2026 at Ptc Therapeutics, up from -$1.4 billion in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $866.6 million in Q1 2025 to a low of -$1.4 billion in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged -$124.0 million across 5 years, with a median of -$109.3 million in 2022.
• Biggest YoY gain for Net Income towards Common Stockholders was 1046.28% in 2025; the steepest drop was 1984.71% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$170.9 million in 2022, then rose by 8.83% to -$155.8 million in 2023, then soared by 57.71% to -$65.9 million in 2024, then sank by 1984.71% to -$1.4 billion in 2025, then soared by 99.8% to -$2.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.8 million (Q1 2026), -$1.4 billion (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.